Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Amit Sharma, Jerry Yee, Shravanthi R. Gandra, Irfan Khan & Jeffrey Petersen. (2010) Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Current Medical Research and Opinion 26:11, pages 2679-2687.
Read now
Read now
Articles from other publishers (18)
Takahiro Yajima, Kumiko Yajima & Hiroshi Takahashi. (2021) Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients. PLOS ONE 16:1, pages e0245625.
Crossref
Crossref
Ylenia Ingrasciotta, Janet Sultana, Dario Formica, Valentina Ientile, Andrea Aiello, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Mariangela Rossi, Domenico Santoro & Gianluca Trifirò. (2020) Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?. Pharmacoepidemiology and Drug Safety 30:1, pages 65-77.
Crossref
Crossref
Pascal Chanu, Franz Schaefer, Bradley A. Warady, Claus Peter Schmitt, Bruno Reigner, Gabriel Schnetzler, Sylvie Meyer Reigner, Mark Eisner, Arlette Weichert & Nicolas Frey. (2020) Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. British Journal of Clinical Pharmacology 86:4, pages 801-811.
Crossref
Crossref
Masaki Higashiura, Masaki Ohya, Yusuke Tanaka, Takuro Yano, Shuto Yamamoto, Toru Mima, Shigeo Negi & Takashi Shigematsu. (2020) Correlation between haemoglobin level and type of erythropoiesis-stimulating agent at initiation of haemodialysis. International Journal of Clinical Pharmacy 42:2, pages 635-641.
Crossref
Crossref
Teppei Okamoto, Shingo Hatakeyama, Yoshimi Tanaka, Kengo Imanishi, Tooru Takashima, Fumitada Saitoh, Takuya Koie, Tadashi Suzuki & Chikara Ohyama. (2018) Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study. Clinical and Experimental Nephrology 22:5, pages 1174-1181.
Crossref
Crossref
Luiz H. ArantesJr.Jr., Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte & Jay Wish. (2018) A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Critical Reviews in Oncology/Hematology 129, pages 79-90.
Crossref
Crossref
Michio Kuwahara, Syoko Hasumi, Shintaro Mandai, Tomomi Tanaka, Satomi Shikuma, Wataru Akita, Yoshihiro Mori & Sei Sasaki. (2013) Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Clinical and Experimental Nephrology 18:5, pages 755-762.
Crossref
Crossref
Bassam Bernieh, Samra Abouchacra, Yousef Boobes, Mohammad R. Al Hakim, Nico Nagelkerke, Ahmad Chaaban, Mohamad Ahmed, Qutaiba Hussain, Hanan El Jack, Faiz Abayechi, Imran Khan & Nicole Gebran. (2014) Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. International Urology and Nephrology 46:2, pages 453-459.
Crossref
Crossref
Terumi Higuchi, Yumiko Ishikawa, Toshio Yamazaki, Mari Mizuno, Erina Okawa, Harumi Setoguchi, Junko Yanagisawa, Shiori Nakajima, Hideyuki Ando, Osamu Oikawa, Atsushi Inoshita, Masanori Abe, Takahiro Ueno & Masayoshi Soma. (2014) Efficacy of levocarnitine for renal anemia in hemodialysis patients. Nihon Toseki Igakkai Zasshi 47:2, pages 119-127.
Crossref
Crossref
Terumi Higuchi, Yumiko Ishikawa, Toshio Yamazaki, Mari Mizuno, Erina Okawa, Harumi Setoguchi, Junko Yanagisawa, Mika Yoshizawa, Nami Horinouchi, Mie Yusa, Miyuki Hayase & Hideyuki Ando. (2013) Investigation of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in hemodialysis patients. Nihon Toseki Igakkai Zasshi 46:7, pages 641-649.
Crossref
Crossref
Terumi Higuchi, Yumiko Ishikawa, Sunao Hotta, Shinichi Enomoto, Tomoya Takasaki, Takayuki Niikura, Shinya Yamamichi, Harumi Setoguchi, ,Shiori Nakajima, Junko Yanagisawa, Ayako Ono, Mitsuko Kumada, Fusako Ishikawa, Nami Horinouchi, Toshio Yamazaki, Mari Mizuno, Erina Okawa & Hideyuki Ando. (2013) Associations between brachial-ankle pulse wave velocity (baPWV) and clinical parameters in hemodialysis patients. Nihon Toseki Igakkai Zasshi 46:6, pages 551-559.
Crossref
Crossref
Terumi Higuchi, Yoshihiro Mano, Yumiko Ishikawa, Sunao Hotta, Toshio Yamazaki, Mari Mizuno, Erina Okawa, Harumi Setoguchi, Ikue Nagata, Kyoko Nikaido, Erika Shiraishi, Mie Yusa, Nami Horinouchi, Shinichi Enomoto & Hideyuki Ando. (2012) Links between plasma 8-hydroxy-2'-deoxyguanosine(8-OHdG）and various parameters in hemodialysis patients. Nihon Toseki Igakkai Zasshi 45:11, pages 1035-1043.
Crossref
Crossref
R. Ravasio, C. Cerra & S. Migliazza. (2013) Cinque anni di utilizzo degli agenti stimolanti l’eritropoiesi nella terapia dell’anemia indotta da insufficienza renale nell’ASL di PaviaFive-year period of erythropoietin receptor agonists utilization in the treatment of anemia in patients with chronic kidney disease in the Local Health Unit of Pavia. PharmacoEconomics Italian Research Articles 13:2, pages 65-80.
Crossref
Crossref
R. Ravasio, M. D’Orsi, G. F. Zuccotti, A. Girlanda, D. Cantù, C. Buffa & M. De Petris. (2013) Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica: l’esperienza della ASL della provincia di AlessandriaEvaluation of dosages and costs associated with the use of erythropoietin receptor agonists in the treatment of anemia in patients with chronic kidney disease: the Local Health Unit of Alessandria experience. PharmacoEconomics Italian Research Articles 12:3, pages 167-174.
Crossref
Crossref
Varun Agrawal, Sudipto Mukherjee, Rajani Kosuri & Francis Dumler. (2010) Anemia Management With Darbepoetin-Alfa in Outpatient Hemodialysis Patients Switched From Epoetin-Alfa: A Community Hospital Experience. American Journal of Therapeutics 17:5, pages 469-475.
Crossref
Crossref
ZINA S VALAYDON, PETROVA LEE, GEORGE L DALE, ANDRZEJ S JANUSZEWSKI, KEVIN G ROWLEY, HARSHAL NANDURKAR, CONNIE KARSCHIMKUS, JAMES D BEST, TIMOTHY J LYONS & ALICIA J JENKINS. (2009) Increased coated-platelet levels in chronic haemodialysis patients. Nephrology 14:2, pages 148-154.
Crossref
Crossref
Wen-Yi Li, Tzong-Shinn Chu, Jenq-Wen Huang, Ming-Shiou Wu & Kwan-Dun Wu. (2008) Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis. Journal of the Formosan Medical Association 107:11, pages 843-850.
Crossref
Crossref
R. Ravasio, C. Cerra & P. Fratino. (2013) Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronicaEvaluation of dosages and costs associated with the use of erythropoietin receptor agonists in the treatment of anemia in patients with chronic kidney disease. PharmacoEconomics Italian Research Articles 10:3, pages 161-169.
Crossref
Crossref